NAmur Research Institute for LIfe Sciences
Jean-Michel Dogné
Laboratory investigations in hemostasis
Optimizing the clinical management and understanding the physiopathological mechanisms underlying thrombotic pathologies. Hemocompatibility testing of biomaterials & Nanotoxicology
Prof. Jean-Michel Dogné PharmD, PhD
UNamur, Department of pharmacy
Member of the Namur Nanosafety Center (NNC)
Member of the Namur Medicine & Drug Innovation Center (NAMEDIC)
Research portal UNamur | ORCID | ResearchGate | LinkedIn
Expertise and research interests
Jean-Michel Dogné obtained his Pharm. D. from the University of Liège in 1996 and continued his studies in the laboratory of medicinal chemistry at the same university, where he received his Ph.D. in pharmaceutical sciences in November 2000. He was appointed Professor at the University of Namur in 2005 where he is currently head of the Department of Pharmacy. His research interests include the development and monitoring of antiplatelet and anticoagulant agents, the hemocompatibility of biomaterials and nanotoxicology.
Prof. Jean-Michel Dogné is leading research projects in the field of thrombosis and hemostasis. His research activities contribute to optimizing the clinical management of thrombotic pathologies and to understanding the physiopathological mechanisms underlying the disease. He has been studying drug-induced thrombosis in patients with malignancy and shed light on extracellular vesicle-mediated anti-cancer drug resistance.
Moreover, Jean-Michel Dogné has a strong expertise in hemocompatibility testing of biomaterials and safety evaluation of nanoparticles. He was involved in several large-scale European projects such as NANOGECO and NANOHEART.
More recently, in response to the coronavirus pandemic, he is participating in clinical laboratory investigations related to Covid-19.
He is member of the Pharmacovigilance Risk Assessment Committee (PRAC) of the EMA since 2012 and the Global Advisory Committee on Vaccine Safety (GASVS) of the WHO since 2020.
Group members
PhD students: Emma Boretti, Alice De Groote, Happy Phanio Djokoto, Marie Didembourg, Constant Gillot and Natalie Lan Linh Tran
Research projects
- ONGOING Optimization of in silico data evaluation (pharmacokinetic and pharmacodynamic models) used in drug development. Ongoing PhD thesis by Happy Phanio Djokoto. Under co-supervision by Prof. Flora Musuamba Tshinanu, AFMPS and Prof. Jean-Michel Dogné, UNamur.
- ONGOING The role of non-hormonal therapies in managing menopausal symptoms. Ongoing PhD thesis by Emma Boretti. Under co-supervision by Prof. Jonathan Douxfils (promoter), Prof. Charlotte Beaudart (co-promoter) and Prof. Jean-Michel Dogné (co-promoter).
Thrombosis and hemostasis
- ONGOING The THROMBIMMUN project: Relationship between inflammation, immunity and thrombosis. Ongoing PhD thesis by Constant Gillot. Under co-supervision by Prof. Jonathan Douxfils (promoter) and Prof. Jean-Michel Dogné (co-promoter).
- ONGOING The HIC project: Evaluation of hormone-induced coagulopathy. Ongoing PhD thesis by Marie Didembourg. Under co-supervision by Prof. Jonathan Douxfils (promoter) and Prof. Jean-Michel Dogné (co-promoter).
- ONGOING The MAS project: Measure And See the activity of direct oral anticoagulant in the clinical context. Research collaboration between UNamur (Prof. Jonathan Douxfils, Prof. Jean-Michel Dogné, Romain Siriez), Clinique Saint-Luc Bouge (Julien Favresse) and CHU UCL Namur (Prof. François Mullier and Dr. Michaël Hardy).
- ONGOING The AVRI project: Evaluation of the risk of radiotherapy-induced atherosclerosis. Research collaboration between UNamur (Prof. Jonathan Douxfils, Prof. Jean-Michel Dogné, Dr. Céline Bouvy) and ULiège (Prof. Cécile Oury, Nathalie Donis).
- . PhD thesis by Romain Siriez on 06/07/2022. Under co-supervision by Prof. Jonathan Douxfils (promoter), Prof. Jean-Michel Dogné (co-promoter), Dr. Julie Laloy (co-promoter).
- Implication of microparticles in thrombosis associated with paroxysmal nocturnal hemoglobinuria. PhD thesis defended by Bérangère Devalet on 28/01/2020. Under co-supervision by Prof. Jean-Michel Dogné, UNamur (promoter) and Prof. Christian Chatelain, CHU UCL Namur, Hematology department (co-promoter).
- Exploring adverse drug reactions associated with the use of direct oral anticoagulants: From greater fundamental knowledge to better clinical prevention. PhD thesis defended by Anne-Laure Sennesael on 13/09/2018. Under co-supervision by Prof. Anne Spinewine, UCLouvain, LDRI (promoter) and Prof. Jean-Michel Dogné, UNamur, NARILIS (co-promoter).
- Study of the potential role of extracellular vesicles in thrombosis associated with paroxysmal nocturnal hemoglobinuria and red blood cell concentrates transfusions. PhD thesis defended by Adeline Wannez on 12/09/2018. Under co-supervision by Prof. Jean-Michel Dogné, UNamur (promoter) and Prof. François Mullier, CHU UCL Namur, Hematology laboratory (promoter).
- Analytical and clinical validation of sensitive assays for the diagnosis of immune heparin-induced thrombocytopenia. PhD thesis defended by Valentine Minet on 08/11/2017. Under co-supervision by Prof. Jean-Michel Dogné, UNamur (promoter) and Prof. François Mullier, CHU UCL Namur, Hematology laboratory (co-promoter).
- PhD thesis defended by Céline Bouvy on 16/10/2017. Under co-supervision by Prof. Jean-Michel Dogné, UNamur (promoter) and Prof. Christian Chatelain, CHU UCL Namur, Hematology department (co-promoter)
- Design, synthesis and evaluation of coagulation FXIIa, inhibitors as potential antithrombotic agents. PhD thesis defended by Charlotte Bouckaert on 16/05/2017. Under co-supervision by Dr. Lionel Pochet (promoter) and Prof. Jean-Michel Dogné (co-promoter).
- Study of the underlying mechanism of the hypercoagulable state in acute leukaemia and impact of specific treatments on the thrombotic risk. PhD thesis defended by Damien Gheldof on 22/10/2015. Under co-supervision by Prof. Christian Chatelain, CHU UCL Namur, Hematology department (promoter) and Prof. Jean-Michel Dogné, UNamur (co-promoter).
Hemocompatibility of biomaterials - Nanotoxicology
- ONGOING Toxicology of microplastic particles. Ongoing PhD thesis by Alice De Groote.
- ONGOING Nano4Life: Innovative multidrug nanomedicines for myocardial ischemia reperfusion injuries treatment. Ongoing PhD thesis by Natalie Lan Linh Tran. Joint PhD programme at UNamur (Prof. Jean-Michel Dogné) and Université Paris-Saclay (Prof. Patrick Couvreur).
- NANOHEART : Squalene-Adenosine nanoparticles for heart ischemia/reperfusion injuries treatment. EuroNanoMed III project. Coordinated by Université Paris-Saclay (Prof. Patrick Couvreur). In collaboration with UNamur, NARILIS (Prof. Jean-Michel Dogné and Dr. Julie Laloy).
- NanoToxClass: Establishing nanomaterial grouping / classification strategies according to toxicity and biological effects for supporting risk assessment. ERA-NET project on Nanosafety. Coordinated by German Federal Institute for Risk Assessment. In collaboration with UNamur (Prof. Jean-Michel Dogné and Dr. Julie Laloy): In vivo inhalation studies to support nanomaterial grouping using a multi-omics approach.
- NANOGECO: Nanoparticle generation by atomization processes in spray coating. ERA-NET project on Nanosafety. Coordinated by UNamur ((Prof. Jean-Michel Dogné and Dr. Julie Laloy).
- ESTELIP: Development of liposomes encapsulating estetrol to prevent cerebral ischemia of premature babies. WB Health project. Coordinated by ULiège, CIRM (Dr. Géraldine Piel). In collaboration with UNamur (Prof. Jean-Michel Dogné and Dr. Julie Laloy).
SARS-CoV-2
|
Selected publications
Didembourg M, Locquet M, Raskin L, Tchimchoua BT, Dogné JM, Beaudart C, Douxfils J. Lower reporting of venous thromboembolisms events with natural estrogen-based COCs compared to ethinylestradiol containing pills: A disproportionality analysis of the Eudravigilance database. Contraception. 2024 Oct 16:110727.
Douxfils J, Beaudart C, Dogné JM. Risk of neoplasm with the neurokinin 3 receptor antagonist fezolinetant. Lancet. 2023 Oct 18:S0140-6736(23)01634-3.
Bizimungu C, Sabbe M, Wuillaume F, Hamdani J, Koch P, Dogné JM. Challenges in Assessing COVID-19 Vaccines Safety Signals-The Case of ChAdOx1 nCoV-19 Vaccine and Corneal Graft Rejection. Vaccines (Basel). 2023 May 6;11(5):954.
Gillot C, Bayart JL, Closset M, Cabo J, Maloteau V, Dogné JM, Douxfils J, Favresse J. Peri-infection titers of neutralizing and binding antibodies as a predictor of COVID-19 breakthrough infections in vaccinated healthcare professionals: importance of the timing. Clin Chem Lab Med. 2023 Apr 3;61(9):1670-1675.
Evrard J, Siriez R, Bouvy C, Favresse J, Yildiz H, Hainaut P, Mullier F, Dogné JM, Douxfils J. Comparison of analytical performances between clot waveform analysis and FibWave in edoxaban-treated patients and healthy controls. Res Pract Thromb Haemost. 2022 Nov 4;6(7):e12804.
Favresse J, Gillot C, Bayart JL, David C, Simon G, Wauthier L, Closset M, Dogné JM, Douxfils J. Vaccine-induced binding and neutralizing antibodies against Omicron 6 months after a homologous BNT162b2 booster. J Med Virol. 2022 Sep 21;10.1002/jmv.28164.
Favresse J, Bayart JL, David C, Gillot C, Wieërs G, Roussel G, Sondag G, Elsen M, Eucher C, Dogné JM, Douxfils J. Serum SARS-CoV-2 Antigens for the Determination of COVID-19 Severity. Viruses. 2022 Jul 28;14(8):1653.
Favresse J, Bayart JL, Mullier F, Elsen M, Eucher C, Eeckhoudt SV, Roy T, Wieers G, Laurent C, Dogné JM, Closset M, Douxfils J. Antibody titers decline 3-month post-vaccination with BNT162b2. Emerg Microbes Infect. 2021 Jul 7:1-8.
Favresse J, Gillot C, Oliveira M, Cadrobbi J, Elsen M, Eucher C, Laffineur K, Rosseels C, Van Eeckhoudt S, Nicolas JB, Morimont L, Dogné JM, Douxfils J. Head-to-Head Comparison of Rapid and Automated Antigen Detection Tests for the Diagnosis of SARS-CoV-2 Infection. J Clin Med. 2021 Jan 13;10(2):E265.
Douxfils J, Favresse J, Dogné JM, Lecompte T, Susen S, Cordonnier C, Lebreton A, Gosselin R, Sié P, Pernod G, Gruel Y, Nguyen P, Vayne C, Mullier F. Hypotheses behind the very rare cases of thrombosis with thrombocytopenia syndrome after SARS-CoV-2 vaccination. Thromb Res. 2021 Jul;203:163-171.
Evrard J, Hardy M, Dogné JM, Lessire S, Maloteau V, Mullier F, Douxfils J. Are the DOAC plasma level thresholds appropriate for clinical decision-making? A reappraisal using thrombin generation testing. Int J Lab Hematol. 2021 Feb;43(1):e48-e51.
Siriez R, Alpan L, Elasaad K, Devel P, Laloy J, Dogné JM, Douxfils J. Importance of measuring pharmacologically active metabolites of edoxaban: development and validation of an ultra-high-performance liquid chromatography coupled with a tandem mass spectrometry method. J Thromb Thrombolysis. 2020 Apr;49(3):395-403.
Evrard J, Morimont L, Didembourg M, Haguet H, Siriez R, Dogné JM, Douxfils J. Assessment of acquired activated protein C resistance with the FibWave and comparison with the ETP-based APC resistance. Int J Lab Hematol. 2020 Dec 12.
Haguet H, Bouvy C, Delvigne AS, Modaffari E, Wannez A, Sonveaux P, Dogné JM, Douxfils J. The Risk of Arterial Thrombosis in Patients With Chronic Myeloid Leukemia Treated With Second and Third Generation BCR-ABL Tyrosine Kinase Inhibitors May Be Explained by Their Impact on Endothelial Cells: An In-Vitro Study. Front Pharmacol. 2020 Jul 3;11:1007.
Haguet H, Graux C, Mullier F, Dogné JM, Douxfils J. Long-Term Survival, Vascular Occlusive Events and Efficacy Biomarkers of First-Line Treatment of CML: A Meta-Analysis. Cancers (Basel). 2020 May 15;12(5):E1242.
Siriez R, Alpan L, Elasaad K, Devel P, Laloy J, Dogné JM, Douxfils J. Importance of measuring pharmacologically active metabolites of edoxaban: development and validation of an ultra-high-performance liquid chromatography coupled with a tandem mass spectrometry method. J Thromb Thrombolysis. 2020 Apr;49(3):395-403.
Evrard J, Morimont L, Didembourg M, Haguet H, Siriez R, Dogné JM, Douxfils J. Assessment of acquired activated protein C resistance with the FibWave and comparison with the ETP-based APC resistance. Int J Lab Hematol. 2020 Dec 12.
Devalet B, Wannez A, Bailly N, Alpan L, Gheldof D, Douxfils J, Bihin B, Chatelain B, Dogné JM, Chatelain C, Mullier F. Prospective and comparative study of paroxysmal nocturnal hemoglobinuria patients treated or not by eculizumab: Focus on platelet extracellular vesicles. Medicine (Baltimore). 2019 Jul;98(27):e16164.
Sennesael AL, Larock AS, Devalet B, Mathieux V, Verschuren F, Muschart X, Dalleur O, Dogné JM, Spinewine A. Preventability of serious thromboembolic and bleeding events related to the use of oral anticoagulants: a prospective study. Br J Clin Pharmacol. 2018 Jul;84(7):1544-1556.
Bouvy C, Wannez A, George F, Graux C, Chatelain C, Dogné JM. Circulating MicroRNAs as Biomarkers in Diffuse Large B-cell Lymphoma: A Pilot Prospective Longitudinal Clinical Study. Biomark Cancer. 2018 Jun 18;10:1179299X18781095.
Lessire S, Douxfils J, Pochet L, Dincq AS, Larock AS, Gourdin M, Dogné JM, Chatelain B, Mullier F. Estimation of Rivaroxaban Plasma Concentrations in the Perioperative Setting in Patients With or Without Heparin Bridging. Clin Appl Thromb Hemost. 2018 Jan;24(1):129-138.
Wannez A, Devalet B, Bouvy C, Laloy J, Bihin B, Chatelain B, Chatelain C, Dogné JM, Mullier F. Eculizumab decreases the procoagulant activity of extracellular vesicles in paroxysmal nocturnal hemoglobinuria: A pilot prospective longitudinal clinical study. Thromb Res. 2017 Jun 9;156:142-148.
Minet V, Baudar J, Bailly N, Douxfils J, Laloy J, Lessire S, Gourdin M, Devalet B, Chatelain B, Dogné JM, Mullier F. Rapid exclusion of the diagnosis of immune HIT by AcuStar HIT and heparin-induced multiple electrode aggregometry. Thrombosis research 2014, 133:1074-1078.
Laloy J, Minet V, Alpan L, Mullier F, Beken S, Toussaint O, Lucas S, Dogné JM. Impact of Silver Nanoparticles on Haemolysis, Platelet Function and Coagulation. Nanobiomedicine (Rij). 2014 Jan 1;1:4.
